Volumina Medical closes its Series A funding to further develop its lead product Adipearl
04.10.2022
Spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL), Volumina Medical is developing highly innovative biomaterials for regenerative medicine. Their solutions address high unmet needs for the markets of reconstructive and plastic surgery. Volumina’s first product is Adipearl – a leading innovative biomaterial being developed to support the repair of soft tissues – initially targeting breast reconstruction after cancer surgery. The startup announced that it has raised an undisclosed amount in a Series A fundraising. The round involved existing investors and notable new investors, including Clinique La Prairie and Skyviews Life Science Ltd.
 Amélie Béduer, PhD, founder and CEO of Volumina Medical
|
 |
At present, around 2 million women are diagnosed with breast cancer each year worldwide, 500,000 of whom are in Europe. These patients increasingly resort to reconstructive surgeries after tumor resection to regain their natural and healthy physical appearance. Unfortunately, today, the available techniques are either too burdensome, induce long-term foreign body reactions, require repeated surgeries, or do not bring durable results. In addition, a high number of patients are not eligible for one of these techniques and remain untreated.
To address this significant unmet medical need, Volumina Medical has been working for a number of years on the development of a platform of novel injectable biomaterials to support soft tissue repair. The lead product from this work is AdipearlTM which has gone through extensive pre-clinical studies and is now being tested in patients. The first therapeutic target is breast reconstruction following cancer surgery.
Amélie Béduer, CEO of Volumina Medical said: “With the additional investment, we are in an excellent position to strengthen the team and speed up our development. We are also very pleased to have, among our new investors, additional experts in our field, as well as renowned Therapeutic Area Experts.”
Volumina Medical also welcomes new members to its Board of Directors: among them, Silvia Scherer, who has 25 years of experience in health care, aesthetics, and cosmetics as a businesswoman and an entrepreneur, and Prof. Stefan Catsicas, managing partner of Skyviews Life Science, former CTO and Executive Board member of Nestlé Global, who was also chairman of cell biology at the School of Medicine of Lausanne and Vice President Research of EPFL.
Simone Gibertoni, CEO of Clinique La Prairie Group, and Stefan Catsicas, said: “We are delighted by this first collaboration between our two institutions, as Volumina is a flagship of Swiss and EPFL research, addressing a major worldwide unmet need in women's health.”
Volumina Medical won a Venture Kick award in 2018 and was one of the Venture Leaders Life Sciences in 2019. In addition, the startup was featured at the TOP 100 Swiss Startup Award in 2018, 2019, 2020, and 2021.
Located in Montreux, Clinique La Prairie was founded in 1931 by Professor Paul Niehans, a pioneer in the science of longevity. Over the years, the resort has established itself as a world-renowned medical clinic with five-star hospital facilities, advanced medical equipment, and a medical team of over 50 specialists. Its philosophy is based on four pillars: Medical, Well-being,
Nutrition and Mouvement.
Skyviews Life Science Ltd., based in the Isle of Man and part of Precision Health Corp. PCC Ltd., is a privately held investment company specialised in longevity. They identify investment opportunities in companies at the growing interface between biotechnology, advanced nutrition and digital health. Skyviews targets private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods that will improve people’s quality of life.
Source: Volumina Medical press release and website.
To address this significant unmet medical need, Volumina Medical has been working for a number of years on the development of a platform of novel injectable biomaterials to support soft tissue repair. The lead product from this work is AdipearlTM which has gone through extensive pre-clinical studies and is now being tested in patients. The first therapeutic target is breast reconstruction following cancer surgery.
Amélie Béduer, CEO of Volumina Medical said: “With the additional investment, we are in an excellent position to strengthen the team and speed up our development. We are also very pleased to have, among our new investors, additional experts in our field, as well as renowned Therapeutic Area Experts.”
Volumina Medical also welcomes new members to its Board of Directors: among them, Silvia Scherer, who has 25 years of experience in health care, aesthetics, and cosmetics as a businesswoman and an entrepreneur, and Prof. Stefan Catsicas, managing partner of Skyviews Life Science, former CTO and Executive Board member of Nestlé Global, who was also chairman of cell biology at the School of Medicine of Lausanne and Vice President Research of EPFL.
Simone Gibertoni, CEO of Clinique La Prairie Group, and Stefan Catsicas, said: “We are delighted by this first collaboration between our two institutions, as Volumina is a flagship of Swiss and EPFL research, addressing a major worldwide unmet need in women's health.”
The Volumina Medical management team: Prof. Philippe Renaud, Amélie Béduer, PhD, and Prof. Thomas Braschler
Volumina Medical won a Venture Kick award in 2018 and was one of the Venture Leaders Life Sciences in 2019. In addition, the startup was featured at the TOP 100 Swiss Startup Award in 2018, 2019, 2020, and 2021.
Located in Montreux, Clinique La Prairie was founded in 1931 by Professor Paul Niehans, a pioneer in the science of longevity. Over the years, the resort has established itself as a world-renowned medical clinic with five-star hospital facilities, advanced medical equipment, and a medical team of over 50 specialists. Its philosophy is based on four pillars: Medical, Well-being,
Nutrition and Mouvement.
Skyviews Life Science Ltd., based in the Isle of Man and part of Precision Health Corp. PCC Ltd., is a privately held investment company specialised in longevity. They identify investment opportunities in companies at the growing interface between biotechnology, advanced nutrition and digital health. Skyviews targets private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods that will improve people’s quality of life.
Source: Volumina Medical press release and website.